Free Trial
→ Uranium Mine Flood That Sparked a 2006 Price Surge Returns (From Digest Publishing) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
AbbVie Inc. stock logo
ABBV
AbbVie
$294.10
-0.1%		$274.82
$190.75
▼
$302.93
$519.95B0.26.29 million shs1.14 million shs
Equinix, Inc. stock logo
EQIX
Equinix
$1,054.98
-1.7%		$1,018.86
$720.62
▼
$1,128.68
$104.03B0.98596,397 shs110,048 shs
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
$285.98
+0.9%		$266.83
$193.55
▼
$288.11
$688.39B0.227.93 million shs1.97 million shs
7 Energy Stocks to Buy and Hold Forever Cover
7 Energy Stocks to Buy and Hold Forever

Oil still powers the global economy, but AI is reshaping the energy opportunity. Discover seven stocks spanning traditional energy, infrastructure, and next-generation power.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
AbbVie Inc. stock logo
ABBV
AbbVie
-0.06%+2.18%+7.25%+18.28%+26.28%
Equinix, Inc. stock logo
EQIX
Equinix
+0.44%+7.56%+5.24%-2.66%+31.91%
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
+1.13%+4.11%+13.98%+8.93%+45.84%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
AbbVie Inc. stock logo
ABBV
AbbVie
$294.10
-0.1%		$274.82
$190.75
▼
$302.93
$519.95B0.26.29 million shs1.14 million shs
Equinix, Inc. stock logo
EQIX
Equinix
$1,054.98
-1.7%		$1,018.86
$720.62
▼
$1,128.68
$104.03B0.98596,397 shs110,048 shs
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
$285.98
+0.9%		$266.83
$193.55
▼
$288.11
$688.39B0.227.93 million shs1.97 million shs
7 Energy Stocks to Buy and Hold Forever Cover
7 Energy Stocks to Buy and Hold Forever

Oil still powers the global economy, but AI is reshaping the energy opportunity. Discover seven stocks spanning traditional energy, infrastructure, and next-generation power.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
AbbVie Inc. stock logo
ABBV
AbbVie
-0.06%+2.18%+7.25%+18.28%+26.28%
Equinix, Inc. stock logo
EQIX
Equinix
+0.44%+7.56%+5.24%-2.66%+31.91%
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
+1.13%+4.11%+13.98%+8.93%+45.84%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
AbbVie Inc. stock logo
ABBV
AbbVie
2.83
Moderate Buy$297.460.86% Upside
Equinix, Inc. stock logo
EQIX
Equinix
2.94
Moderate Buy$1,234.1317.80% Upside
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
2.73
Moderate Buy$275.92-3.92% Downside

Current Analyst Ratings Breakdown

Latest ABBV, EQIX, and JNJ Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
11/4/2026
AbbVie Inc. stock logo
ABBV
AbbVie
BMO Capital Markets logo
BMO Capital Markets
Subscribe to MarketBeat All Access to unlock brokerage rankings
Set Price Target$315.00
11/2/2026
AbbVie Inc. stock logo
ABBV
AbbVie
Sanford C. Bernstein logo
Sanford C. Bernstein
Subscribe to MarketBeat All Access to unlock brokerage rankings
Reiterated RatingMarket Perform$275.00
11/2/2026
AbbVie Inc. stock logo
ABBV
AbbVie
Guggenheim logo
Guggenheim
Subscribe to MarketBeat All Access to unlock brokerage rankings
Boost Price TargetBuy$288.00 ➝ $322.00
11/2/2026
Equinix, Inc. stock logo
EQIX
Equinix
BMO Capital Markets logo
BMO Capital Markets
Subscribe to MarketBeat All Access to unlock brokerage rankings
Reiterated RatingOutperform$1,250.00
11/2/2026
AbbVie Inc. stock logo
ABBV
AbbVie
Wells Fargo & Company logo
Wells Fargo & Company
Subscribe to MarketBeat All Access to unlock brokerage rankings
Boost Price TargetOverweight$300.00 ➝ $340.00
11/2/2026
AbbVie Inc. stock logo
ABBV
AbbVie
UBS Group AG logo
UBS Group
Subscribe to MarketBeat All Access to unlock brokerage rankings
Boost Price TargetNeutral$275.00 ➝ $295.00
11/2/2026
AbbVie Inc. stock logo
ABBV
AbbVie
Leerink Partners logo
Leerink Partners
Subscribe to MarketBeat All Access to unlock brokerage rankings
Boost Price TargetOutperform$309.00 ➝ $342.00
11/2/2026
AbbVie Inc. stock logo
ABBV
AbbVie
Morgan Stanley logo
Morgan Stanley
Subscribe to MarketBeat All Access to unlock brokerage rankings
Boost Price TargetOverweight$310.00 ➝ $346.00
11/2/2026
AbbVie Inc. stock logo
ABBV
AbbVie
Royal Bank Of Canada logo
Royal Bank Of Canada
Subscribe to MarketBeat All Access to unlock brokerage rankings
Boost Price TargetOutperform$280.00 ➝ $330.00
11/2/2026
AbbVie Inc. stock logo
ABBV
AbbVie
Cantor Fitzgerald logo
Cantor Fitzgerald
Subscribe to MarketBeat All Access to unlock brokerage rankings
Boost Price TargetOverweight$290.00 ➝ $325.00
11/2/2026
AbbVie Inc. stock logo
ABBV
AbbVie
Canaccord Genuity Group Inc. logo
Canaccord Genuity Group
Subscribe to MarketBeat All Access to unlock brokerage rankings
Boost Price TargetBuy$290.00 ➝ $338.00
(Data available from 11/13/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
AbbVie Inc. stock logo
ABBV
AbbVie
$61.16B8.52$15.14 per share19.48($2.57) per share-114.76
Equinix, Inc. stock logo
EQIX
Equinix
$9.22B11.22$34.13 per share30.70$147.24 per share7.12
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
$94.19B7.34$14.46 per share19.86$33.87 per share8.48
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
AbbVie Inc. stock logo
ABBV
AbbVie
$4.23B$5.8150.8318.411.3415.67%-450.55%16.50%N/A
Equinix, Inc. stock logo
EQIX
Equinix
$1.35B$16.6562.9224.251.5016.38%11.49%3.96%N/A
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
$26.80B$6.6043.5424.842.7716.20%31.64%13.04%1/26/2027 (Estimated)

Latest ABBV, EQIX, and JNJ Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
10/30/2026Q3 2026
AbbVie Inc. stock logo
ABBV
AbbVie
$3.73$3.82+$0.09$2.37$17.32 billion$17.40 billion
10/28/2026Q3 2026
Equinix, Inc. stock logo
EQIX
Equinix
$4.11$4.93+$0.82$4.93$2.56 billion$2.57 billion
10/13/2026Q3 2026
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
$2.53$2.59+$0.06$0.09$25.38 billion$25.40 billion
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
AbbVie Inc. stock logo
ABBV
AbbVie
$6.922.35%+6.80%119.10%53 Years
Equinix, Inc. stock logo
EQIX
Equinix
$20.641.92%+12.01%123.96%10 Years
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
$5.361.89%+5.25%81.21%64 Years

Latest ABBV, EQIX, and JNJ Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
10/29/2026
AbbVie Inc. stock logo
ABBV
AbbVie
quarterly$1.822.47%1/15/20271/15/20272/16/2027
10/28/2026
Equinix, Inc. stock logo
EQIX
Equinix
quarterly$5.162.05%11/18/202611/18/202612/16/2026
10/13/2026
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
quarterly$1.342.15%11/24/202611/24/202612/8/2026
9/10/2026
AbbVie Inc. stock logo
ABBV
AbbVie
quarterly$1.732.44%10/15/202610/15/202611/16/2026
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
AbbVie Inc. stock logo
ABBV
AbbVie
N/A
0.87
0.75
Equinix, Inc. stock logo
EQIX
Equinix
1.59
1.29
1.29
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
0.44
1.02
0.74

Institutional Ownership

CompanyInstitutional Ownership
AbbVie Inc. stock logo
ABBV
AbbVie
70.23%
Equinix, Inc. stock logo
EQIX
Equinix
94.94%
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
69.55%

Insider Ownership

CompanyInsider Ownership
AbbVie Inc. stock logo
ABBV
AbbVie
0.06%
Equinix, Inc. stock logo
EQIX
Equinix
0.27%
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
0.16%
CompanyEmployeesShares OutstandingFree FloatOptionable
AbbVie Inc. stock logo
ABBV
AbbVie
57,0001.77 billion1.77 billionOptionable
Equinix, Inc. stock logo
EQIX
Equinix
13,71698.67 million98.41 millionOptionable
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
138,2002.41 billion2.40 billionOptionable

Recent News About These Companies

Johnson & Johnson stock advances as prostate drug combo enters Phase 3
 |  ad-hoc-news.deA
How Much Does a 69-Year-Old Need Invested in Dividend Stocks to Collect $3,000 a Month?
 |  247wallst.comhttps://247wallst.com/investing/2026/11/13/how-much-does-a-69-year-old-need-invested-in-dividend-stocks-to-collect-3000-a-month/
I Bonds Pay 5.51%. Here’s What Dividend Investors Should Know
 |  247wallst.comhttps://247wallst.com/investing/2026/11/13/i-bonds-pay-5-51-heres-what-dividend-investors-should-know/
170,181 Johnson & Johnson $JNJ Shares Sold by Russell Investments Group Ltd.
November 13 at 6:03 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-170181-johnson-johnson-jnj-shares-sold-by-russell-investments-group-ltd-2026-11-13/
Johnson & Johnson $JNJ Position Raised by Fisher Asset Management LLC
November 13 at 4:27 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-johnson-johnson-jnj-position-raised-by-fisher-asset-management-llc-2026-11-13/
Eurizon Capital SGR S.p.A. Buys 161,643 Shares of Johnson & Johnson $JNJ
November 13 at 4:11 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-eurizon-capital-sgr-spa-buys-161643-shares-of-johnson-johnson-jnj-2026-11-13/
Johnson & Johnson (NYSE:JNJ) Shares Up 1.2% - Still a Buy?
November 12 at 5:19 PM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/price-johnson-johnson-nyse-jnj-shares-up-12-still-a-buy-2026-11-12/
J&J leads Francis Medical investment to fund prostate cancer device
November 12 at 1:27 PM  |  medtechdive.comM
Johnson & Johnson (JNJ) Up 10.4% Since Last Earnings Report: Can It Continue?
November 12 at 1:27 PM  |  finance.yahoo.comhttps://finance.yahoo.com/markets/stocks/articles/johnson-johnson-jnj-10-4-153003339.html
Johnson & Johnson (JNJ) Backs New Cancer Device And Leads $100 Million Depression Bet
November 12 at 1:27 PM  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/johnson-johnson-jnj-backs-cancer-171155980.html
Johnson & Johnson (JNJ) Up 10.4% Since Last Earnings Report: Can It Continue?
November 12 at 12:31 PM  |  zacks.comhttps://www.zacks.com/stock/news/3028852/johnson-johnson-jnj-up-10-4-since-last-earnings-report-can-it-continue?cid=cs-stocknewsapi-ft-realtime_blog-3028852
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Johnson & Johnson - JNJ
November 12 at 10:40 AM  |  prnewswire.comhttps://www.prnewswire.com/news-releases/investor-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-johnson--johnson---jnj-302937484.html
State Street Health Care SPDR (XLV) Adds Eli Lilly and Johnson & Johnson on Nov. 10
November 12 at 8:27 AM  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/state-street-health-care-spdr-110554537.html
Is There A Risk Hiding In Johnson & Johnson Stock's Earnings?
November 12 at 8:27 AM  |  trefis.comT
Johnson & Johnson Sees a Path to Double-Digit Growth by 2030. Is the Dividend King a Buy?
November 11 at 3:31 PM  |  fool.comhttps://www.fool.com/investing/2026/11/11/johnson-johnson-sees-a-path-to-double-digit-growth/?source=marketbeat&utm_source=marketbeat&utm_medium=feed&utm_campaign=article&referring_guid=e2b20134-557b-4627-871e-eab13f264ba3
Johnson & Johnson vs. Eli Lilly: Which Healthcare Giant's Stock Is a Better Buy for 2027?
November 11 at 3:00 PM  |  fool.comhttps://www.fool.com/coverage/better-buy/2026/11/11/johnson-and-johnson-vs-eli-lilly-which-healthcare-giant-s-stock-is-a-better-buy-for-2027/
Johnson & Johnson Sees a Path to Double-Digit Growth by 2030. Is the Dividend King a Buy?
November 11 at 2:57 PM  |  fool.comhttps://www.fool.com/investing/2026/11/11/johnson-johnson-sees-a-path-to-double-digit-growth/
Johnson & Johnson Reports Favorable Data For Bipolar Study
November 11 at 12:51 PM  |  benzinga.comhttps://www.benzinga.com/markets/biotech/26/11/63155674/johnson-johnson-reports-favorable-data-for-bipolar-study
Will HALO's Partner Royalties Drive Growth for the Rest of 2026?
November 11 at 12:24 PM  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/halos-partner-royalties-drive-growth-161100615.html
Massachusetts Woman’s Family Awarded $3.3 Million Against Johnson & Johnson in Mesothelioma Case
November 11 at 12:24 PM  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/dean-omar-branham-shirley-secures-140000404.html
Massachusetts Woman's Family Awarded $3.3 Million Against Johnson & Johnson in Mesothelioma Case
November 11 at 11:36 AM  |  businesswire.comhttps://www.businesswire.com/news/home/20261110467255/en/massachusetts-woman%e2%80%99s-family-awarded-3.3-million-against-johnson-johnson-in-mesothelioma-case/

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
White Tesla sports car parked at a launch site with rocket boosters visible against a sunset sky.
Tesla's Roadster Reveal Hints at 2 Much Bigger Moves
By Sam Quirke | October 19, 2026
AbbVie logo over a laboratory scene with vials, a pipette, and a DNA helix illustration.
AbbVie's Humira Era Is Fading, But Its New Growth Engines Face Another Test
By Thomas Hughes | November 2, 2026
3 Dividend Stocks That Could Pay You No Matter Who Wins the Midterms
3 Stocks With Yields Big Enough to Make Election Volatility Easier to Stomach
By Bridget Bennett | October 23, 2026
A home office desk with a laptop displaying a Daily Market Pulse financial report, beside a coffee mug and notebook.
MarketBeat Week in Review – 11/2 - 11/6
By MarketBeat Staff | November 7, 2026
Assorted pharmaceutical pills, a medicine vial, and a syringe arranged on a laboratory bench.
3 Pharmaceutical Stocks That Offer Safety and Growth
By Chris Markoch | November 12, 2026
AbbVie stock logo

AbbVie NYSE:ABBV

$294.10 -0.35 (-0.12%)
As of 12:11 PM Eastern
This is a fair market value price provided by Massive. Learn more.

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; Ubrelvy for the acute treatment of migraine in adults; and Qulipta for episodic and chronic migraine. In addition, the company offers Ozurdex for eye diseases; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Restasis to increase tear production; and other eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; Janssen Biotech, Inc.; and Genentech, Inc., as well as collaboration with Tentarix Biotherapeutics, LP to develop conditionally-active and multi-specific biologics for oncology and immunology. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Equinix stock logo

Equinix NASDAQ:EQIX

$1,054.98 -17.79 (-1.66%)
As of 12:11 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Equinix (Nasdaq: EQIX) is the world's digital infrastructure company . Digital leaders harness Equinix's trusted platform to bring together and interconnect foundational infrastructure at software speed. Equinix enables organizations to access all the right places, partners and possibilities to scale with agility, speed the launch of digital services, deliver world-class experiences and multiply their value, while supporting their sustainability goals.

Johnson & Johnson stock logo

Johnson & Johnson NYSE:JNJ

$285.98 +2.46 (+0.87%)
As of 12:11 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in the interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas